Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Milane, Lara ^a   Duan, Zhenfeng ^b   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; EOSIN; EPIDERMAL GROWTH FACTOR; GLYCOPROTEIN P; HEMATOXYLIN; HEXOKINASE; HEXOKINASE 2; HYPOXIA INDUCIBLE FACTOR; LACTATE DEHYDROGENASE; LONIDAMINE; NANOPARTICLE; PACLITAXEL; STEM CELL FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDAZOLE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORPHOLOGY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN TARGETING; THROMBOCYTE COUNT; TREATMENT DURATION; TUMOR VOLUME; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; HUMAN; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; SCANNING ELECTRON MICROSCOPY; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALIA; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INDAZOLES; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; NEOPLASMS; P-GLYCOPROTEINS; PACLITAXEL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052552395     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024075     Document Type: Article

References (23)

1. Harris AL, Hochhauser D, (1992) Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31: 205-213.
2. Yague E, Arance A, Kubitza L, O'Hare M, Jat P, et al. (2007) Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res 67: 1130-1137.
3. Harris AL, (2002) Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
4. Semenza GL, (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
5. Gatenby RA, Gillies RJ, (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
6. Semenza G, (2002) Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64: 993-998.
7. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, et al. (2007) Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci U S A 104: 13092-13097.
8. Lopez-Lazaro M, (2008) The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med Chem 8: 305-312.
9. Cosse JP, Michiels C, (2008) Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 8: 790-797.
10. Mathupala SP, Ko YH, Pedersen PL, (2006) Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25: 4777-4786.
11. Pedersen PL, (2007) Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39: 211-222.
12. Del Bufalo D, Biroccio A, Soddu S, Laudonio N, D'Angelo C, et al. (1996) Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J Clin Invest 98: 1165-1173.
13. Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, et al. (2002) Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. Life Sci 71: 2729-2740.
14. Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, et al. (1999) Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 18: 2537-2546.
15. Brawer MK, (2005) Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol 7 (Suppl 7): S21-26.
16. Ditonno P, Battaglia M, Selvaggio O, Garofalo L, Lorusso V, et al. (2005) Clinical Evidence Supporting the Role of Lonidamine for the Treatment of BPH. Rev Urol 7 (Suppl 7): S27-33.
17. Milane L, Duan Z, Amiji M, (2010) Development of EGFR-Targeted Polymer Blend Nanocarriers for Combination Paclitaxel/Lonidamine Delivery To Treat Multi-Drug Resistance in Human Breast and Ovarian Tumor Cells. Mol Pharm.
18. Milane L, Duan ZF, Amiji M, (2011) Biodistribution and Pharmacokinetic Analysis of Combination Lonidamine and Paclitaxel Delivery in an Orthotopic Animal Model of Multi-drug Resistant Breast Cancer Using EGFR-Targeted Polymeric Nanoparticles. Nanomedicine.
19. Han ZB, Ren H, Zhao H, Chi Y, Chen K, et al. (2008) Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis 29: 1853-1861.
20. Semenza GL, (2008) Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60: 591-597.
21. Li Z, Zhao R, Wu X, Sun Y, Yao M, et al. (2005) Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. Faseb J 19: 1978-1985.
22. Song S, Liu D, Peng J, Sun Y, Li Z, et al. (2008) Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm 363: 155-161.
23. Chawla JS, Amiji MM, (2002) Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 249: 127-138.